Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 11/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480997 | 1.00 | KCNA5 (0.73) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL12587918 | 1.00 | KCNA5 (0.73) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL480998 | 1.00 | KCNA5 (0.73) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL13649151 | 0.98 | KCNA5 (0.73) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1243260 | 0.85 | KCNA5 (1.00) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL10461663 | 0.85 | KCNA5 (0.60) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1243557 | 0.84 | KCNA5 (0.64) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL22046668 | 0.84 | KCNA5 (0.55) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1242084 | 0.83 | KCNA5 (1.00) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL12587920 | 0.83 | KCNA5 (1.00) | KCNA5KCNH2CYP2D6CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838678-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-03 | — | — | EP | claimed |
| WO-2006063861-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-22 | — | — | WO | claimed |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-114728168-A | Triazolecarbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021097039-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3383844-B1 | PROCESS FOR THE PREPARATION OF CARBOPROST AND ITS TROMETHAMINE SALT | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 2020-06-03 | — | — | EP | disclosed |
| US-10442762-B2 | Process for the preparation of carboprost and its tromethamine salt | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA ZRT. (HU) | 2019-10-15 | — | — | US | disclosed |
| WO-2007098923-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| EP-1826204-A1 | Process for obtaining enantiomers of duloxetine precursors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-08-29 | — | — | EP | disclosed |
| US-7109349-B2 | Process for obtaining Cizolirtine and its enantiomers | LABORATORIOS DEL DR. ESTEVE, S/A (ES) | 2006-09-19 | — | — | US | disclosed |
| US-7078531-B2 | Process for obtaining enantiomers of thienylazolylalcoxyethanamines | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2006-07-18 | — | — | US | disclosed |
| US-20060135788-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S/A (ES) | 2006-06-22 | — | — | US | disclosed |
| WO-2006063861-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-22 | — | — | WO | disclosed |
| US-20060135787-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF THIENYLAZOLYLALCOXYETHANAMINES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-22 | — | — | US | disclosed |
| EP-1671953-A1 | Process for obtaining cizolirtine and its enantiomers | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-21 | — | — | EP | disclosed |
| EP-1671968-A1 | Process for obtaining enantiomers of thienylazolylalcoxyethanamines | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | KCNA5 3937/4885KCNH2 4318/4885CYP2D6 4007/4885 |
| US-10442762-B2 | Process for the preparation of carboprost and its tromethamine salt | PTGER4, PTGER1, PTGER2 | KCNA5 2983/4885KCNH2 3578/4885CYP2D6 802/4885 |
| US-20060135787-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF THIENYLAZOLYLALCOXYETHANAMINES | PNMT, ADH1A, ADH5 | KCNA5 1355/4885KCNH2 1144/4885CYP2D6 261/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | KCNA5 3937/4885KCNH2 4318/4885CYP2D6 4007/4885 |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | KCNA5 3937/4885KCNH2 4318/4885CYP2D6 4007/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | KCNA5 3937/4885KCNH2 4318/4885CYP2D6 4007/4885 |
| US-20060135788-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | CYP2E1, MAP2K1, MAP2K5 | KCNA5 2432/4885KCNH2 2318/4885CYP2D6 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.